Company Overview | Company Overview

Neuronyx is at the forefront of the cellular therapy revolution with the development of a novel therapy derived from allogeneic human adult bone marrow-derived somatic cells (hABM-SC). These cells have the potential to treat multiple diseases in a broad array of therapeutic categories due to their unique ability to aid the body in repairing damaged tissue, as well as to reduce inflammation and suppress the autoimmune response. These effects have been demonstrated in numerous preclinical studies. hABM-SC have also been safely administered to humans.

Neuronyx’ proprietary expansion process renders hABM-SC a non-differentiating cell therapy which can be manufactured consistently and in very large quantities -- similar to conventional biologics -- using the cells of a single human donor. The end result is a breakthrough cellular therapy which we believe can be universally administered without generating an autoimmune response.